Silence Therapeutics plc (SLN): Entry into a Material Definitive Agreement
Silence Therapeutics plc (SLN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d168365dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 12,962,963 AMERICAN DEPOSITARY SHARES OF THE COMPANY, EACH REPRESENTING THREE ORDINARY SHARES, NOMINAL VALUE £0.05 PER SHARE SILENCE THERAPEUTICS PLC UNDERWRITING AGREEMENT August 11, 2026 JEFFERIES LLC MORGAN STANLEY & CO. LLC
How this was made
The 30-second read
Why it matters
The disclosed ADS issuance increases potential share count and can create short-term selling pressure around pricing and settlement, while also reducing financing risk if proceeds extend runway.
Market read
A new ADS underwriting agreement is a concrete financing catalyst that can drive dilution expectations and near-term volatility.
What to watch
Traders will need the missing details: offering price, gross proceeds, net proceeds, use of funds, and whether it includes any backstop or investor demand signals.
Background
The 8-K reports entry into a material definitive agreement, specifically an underwriting agreement for an ADS offering under an existing shelf registration.
Ticker impact
Silence Therapeutics entered a material definitive underwriting agreement to issue and sell 12,962,963 ADSs, with an option for 1,944,444 more.
Near-term downside or volatility risk from dilution expectations, with direction depending on offering size versus cash needs and deal pricing details not shown here.
This is a primary SEC 8-K disclosure of an underwriting agreement for an ADS offering. The excerpt does not include pricing, proceeds, or use of funds, limiting precision on magnitude and timing of impact.
Market effects
Biopharma issuers can see sentiment spillover when new equity offerings are announced, especially for cash-burn names.
Limited direct regional impact; primarily affects US-listed ADR/ADS liquidity and sentiment for UK-domiciled biotech.
Low global macro relevance; mostly company-specific financing.
Counterpoint
If the offering is priced attractively and funds runway materially, the market may re-rate the balance-sheet risk quickly despite dilution.
Key entities
- issuerSilence Therapeutics plc
Company entering the underwriting agreement for an ADS offering.
- underwriterJefferies LLC
One of the representatives for the underwriters in the ADS offering.
- underwriterMorgan Stanley & Co. LLC
One of the representatives for the underwriters in the ADS offering.
- depositaryThe Bank of New York Mellon
Depositary under the ADS/ADR deposit agreement.
